News

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Using a sample of 350 pregnancies, the maintenance of natalizumab during pregnancy past the 30th week had both positive and negative impacts, suggesting a risk-benefit discussion may be needed before patients begin treatment.

The pediatric REVEAL trial assesses THSA-102 in 2 cohorts of pediatric patients with Rett syndrome due to MECP2 loss-of-function mutation, with results expected in mid-2024.

Neurology News Network for the week ending January 13, 2024. [WATCH TIME: 4 minutes]

Good functional outcome at 90 days was more prevalent among patients on argatroban plus antiplatelet therapy vs antiplatelet alone.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.

A case series highlighted the significance of using multimodal imaging, such as spectral domain OCT, in detecting ocular manifestations in SCA type 7.

Cala Health's transcutaneous afferent patterned stimulation demonstrated significant efficacy in patients with essential tremor, as evidenced by positive outcomes in multiple clinical studies.

The chief medical research officer and head of research at Aviv Clinics talked about the anticipation of long-term results on a randomized controlled trial assessing hyperbaric oxygen therapy, a treatment for long COVID. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Cathleen Lutz, PhD. [LISTEN TIME: 18 minutes]

Brexpiprazole was generally well tolerated over 12 weeks in this vulnerable patient population, with documented efficacy that supported its approval in early 2023.

A recent analysis revealed patients with neuromyelitis optica spectrum disorder exhibited significantly lower vitamin D levels, suggesting a potential association with impaired immune tolerance in the disorder.

Given the low rates of adverse events and benefits to overall health, modifiable risk-reduction strategies could have a significant impact on public health.

The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, discussed recent research that challenged the conventional definitions of sleep and how narcolepsy is often stigmatized. [WATCH TIME: 2 minutes]

The study investigates the potential benefits of ThecaFlex DRx System, an implantable intrathecal catheter, for patients with SMA treated with nusinersen, aiming to reduce the need for serial lumbar punctures and enhance the overall administration experience.

Beth McQuiston, MD, RD, neurologist and medical director at Abbott, discussed the latest developments in traumatic brain injury, such as Abbott’s lab-based blood tests, as well as upcoming publications and guidelines to help with diagnosis.

A recently published study showed patients with Friedreich Ataxia treated with medications that enhanced mitochondrial function demonstrated improvement in clinical outcomes and left ventricular mass index.

Among a cohort of nearly 500 patients, more than half of caregiver respondents reported reductions in seizure frequency alongside improvements in nonseizure-related outcomes.

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesis Hospital talked about the management of poststroke spasticity and highlighted the importance of awareness, education, and early intervention. [WATCH TIME: 5 minutes]

The associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine provided commentary on positive phase 1 findings assessing ALX-001, a highly selective agent in development for neurodegenerative diseases.

Approved in Europe in late 2022, the 24-hour continuous subcutaneous infusion acts as a novel and effective treatment option for patients with advanced levodopa-responsive Parkinson disease.

In addition to showing no significant dose-response relationship with ischemic stroke risk, milvexian was also associated with an increase in major bleeding events.

Over 144 weeks of treatment, patients on CNM-Au8 demonstrated sustained improvements in low contrast vision, working memory, and information processing speed.

The neuroimmunologist at Clínica Alemana de Santiago and head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital discussed Latin American efforts to understand neuromyelitis optica spectrum disorder during the COVID-19 pandemic. [WATCH TIME: 5 minutes]

A recent study identified specific risk factors influencing readmission odds in patients with neuromyelitis optica spectrum disorder, contributing valuable insights for predictive algorithms and improved patient outcomes.

The professor in the department of neurology with McGovern Medical School at UTHealth Houston talked about findings from a recent study that investigated T cell specificity in the spinal fluid of patients with multiple sclerosis. [WATCH TIME: 10 minutes]

Patients with neuromyelitis optica spectrum disorder experienced poor sleep quality, indicating a significant contribution to the overall disease burden.

The associate professor of clinical neurology at University of California, Irvine School of Medicine talked about addressing the critical unmet needs in disability progression among patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Additional data, including secondary end points and other efficacy assessments, are expected to be presented at an upcoming scientific meeting.

The vice president of medical and scientific relations at the Alzheimer’s Association discussed where the organization’s efforts are currently invested and the ways to continue momentum in the Alzheimer disease field. [WATCH TIME: 5 minutes]